Overview

Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

PSSc-001 (LOTUSS) This study is a Phase 2, multinational, open-label, randomized, parallel-group, safety and tolerability study of pirfenidone in participants with systemic sclerosis-related interstitial lung disease (SSc-ILD).

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Pirfenidone